Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 05, 2024 06:05 ET | Source: Recludix Pharma, Inc.

Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease and cancer, today announced that Fierce Biotech has...
May 17, 2024 15:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin Inflammation in Oral Plenary Session at SID Annual Meeting

-- In a preclinical model of psoriasis, the efficacy of oral small molecule REX-7117 was comparable to an anti-IL-17A biologic SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader...
April 23, 2024 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian Ray

Newly appointed head of R&D, Dr. Nirula, joins Recludix from Eli Lilly with over two decades of clinical development experience SAB member, Dr. Ray, has over two decades of experience in...
February 28, 2024 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Participate in Two Investor Conferences in March

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
February 06, 2024 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at Two Investor Conferences in February

SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
November 09, 2023 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Present at Two Investor Conferences in November

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
October 31, 2023 16:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Presents Preclinical Data Demonstrating Strong Efficacy and Favorable Safety Profile of REX-7117 Versus TYK2 and JAK Inhibitors at the Dermatology Drug Development Summit

- REX-7117 found to have superior efficacy to a clinically-relevant dose of deucravacitinib in a preclinical model of psoriasis - REX-7117, as a highly selective STAT3 inhibitor, demonstrates...
October 17, 2023 16:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program at the International Conference of the Inflammation Research Association (IRA)

- Pioneering compounds believed to be the first orally administered reversible inhibitors to bind to and inhibit the SH2 domain potently and selectively - Proprietary STAT3 inhibitors are...
August 30, 2023 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma to Participate in Multiple Investor Conferences in September

SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging targets for inflammatory disease and cancer, today announced that...
July 20, 2023 08:00 ET | Source: Recludix Pharma, Inc.

Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications

- Recludix to receive $125 million in near-term payments and potentially more than $1.2 billion subject to future milestones, and up to double-digit royalties on sales - - Recludix to lead research...